(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 9 October 2003 (09.10.2003)

PCT

(10) International Publication Number WO 2003/083102 A3

- C12N 9/16, (51) International Patent Classification⁷: C12Q 1/42, G01N 33/574, C12Q 1/68, G01N 33/573, A61K 49/00
- (21) International Application Number:

PCT/CA2003/000393

- (22) International Filing Date: 19 March 2003 (19.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/368,859

28 March 2002 (28.03.2002)

- (71) Applicant (for all designated States except US): KINETEK PHARMACEUTICALS, INC. [CA/CA]; 1779 West 75th Avenue, Vancouver, British Columbia V6P 6P2 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): DELANEY, Allen, D. [CA/CA]; 1633 West 65th Avenue, Vancouver, British Columbia V6P 2R2 (CA).
- (74) Agent: SMART & BIGGAR; Kingwell, Brian, G., Box 11560, Vancouver Centre, Suite 2200, 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 22 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CANCER ASSOCIATED PROTEIN PHOSPHATASES AND THEIR USES

(57) Abstract: Detection of expression of the provided phosphatases in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and for determining patient prognosis. The encoded polypeptides further provide a target for screening pharmaccutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further provides methods and compositions relating to agents that specifically bind to MKPX, PTP4A1, PTPN7, FEM-2, DKFZP566K0524 or FLJ20313 for treatment and visualization of tumors in patients.

INTERNATIONAL SEARCH REPORT

PCT/ 3/00393

A. CLASSII IPC 7	FICATION OF SUBJECT MATTER C12N9/16 C12Q1/42 G01N33/5 A61K49/00	574 C12Q1/68	G01N33/573							
According to	According to International Patent Classification (IPC) or to both national classification and IPC									
B. FIELDS SEARCHED										
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C12Q										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched										
Electronic d	ata base consulted during the international search (name of data ba	se and, where practical, search terr	ns used)							
EPO-Internal, Sequence Search, CHEM ABS Data										
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT									
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.							
А	WO 01/012819 A (PLOWMAN GREGORY [MARIO (US); SUGEN INC (US); WHYTE 22 February 2001 (2001-02-22) page 107, line 24 - page 110, lir claims 1-23; figure 3	1-59								
X	WO 01/002581 A (CEPTYR INC ;LUCHE (US); WEI BO (US)) 11 January 2001 (2001-01-11) SEQ ID NO:2	1-59								
X	WO 01/002582 A (CEPTYR INC ;LUCHE (US); WEI BO (US)) 11 January 2001 (2001-01-11) SEQ ID NO:2; Example 2; page 2, page 8; page 43, lines 7 et seq. 1- 98	1–59								
Furth	ner documents are listed in the continuation of box C.	Potent familiu members as	lieled in annu							
		Patent family members as	o noted at atmos.							
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another clation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 										
Date of the	actual completion of the international search	Date of mailing of the internati	ional search report							
10 November 2003 04 03 2004										
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Thiele, U								





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
- [Although claims 7-11, 17-27, 37-40 and 43-59 are directed to a method of treatment of the human/animal body by therapy, diagnosis and surgery, the search has been carried out and based on the alleged effects of the compound/composition.				
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
з	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
	To see the second section of the second seco				
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:				
	see additional sheet				
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.				
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
з	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:				
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.: 1-59 (part)				
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.				

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-59(part)

Inventions relying on the polypeptide having the amino acid sequence set forth in SEQ ID NO:1 or on the nucleic acid sequence comprising the sequence set forth in SEQ ID NO: 2; methods of screening for biologically active agents that modulate a cancer associated phosphatase function; methods for diagnosis of cancer; methods for inhibiting the growth of a cancer cell; methods of screening for targets of a cancer associated phosphatase; methods to treat a tumour; compounds for the treatment of a tumour; methods for visualizing a tumour in a patient

2. claims: 1-59(part)

Inventions relying on the polypeptide having the amino acid sequence set forth in SEQ ID NO:3 or on the nucleic acid sequence comprising the sequence set forth in SEQ ID NO:4; methods of screening for biologically active agents that modulate a cancer associated phosphatase function; methods for diagnosis of cancer; methods for inhibiting the growth of a cancer cell; methods of screening for targets of a cancer associated phosphatase; methods to treat a tumour; compounds for the treatment of a tumour; methods for visualizing a tumour in a patient

3. claims: 1-59(part)

Inventions relying on the polypeptide having the amino acid sequence set forth in SEQ ID NO:5 or on the nucleic acid sequence comprising the sequence set forth in SEQ ID NO:6; methods of screening for biologically active agents that modulate a cancer associated phosphatase function; methods for diagnosis of cancer; methods for inhibiting the growth of a cancer cell; methods of screening for targets of a cancer associated phosphatase; methods to treat a tumour; compounds for the treatment of a tumour; methods for visualizing a tumour in a patient

4. claims: 1-59(part)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Inventions relying on the polypeptide having the amino acid sequence set forth in SEQ ID NO:7 or on the nucleic acid sequence comprising the sequence set forth in SEQ ID NO:8; methods of screening for biologically active agents that modulate a cancer associated phosphatase function; methods for diagnosis of cancer; methods for inhibiting the growth of a cancer cell; methods of screening for targets of a cancer associated phosphatase; methods to treat a tumour; compounds for the treatment of a tumour; methods for visualizing a tumour in a patient

5. claims: 1-59(part)

Inventions relying on the polypeptide having the amino acid sequence set forth in SEQ ID NO:9 or on the nucleic acid sequence comprising the sequence set forth in SEQ ID NO:10; methods of screening for biologically active agents that modulate a cancer associated phosphatase function; methods for diagnosis of cancer; methods for inhibiting the growth of a cancer cell; methods of screening for targets of a cancer associated phosphatase; methods to treat a tumour; compounds for the treatment of a tumour; methods for visualizing a tumour in a patient

6. claims: 1-59(part)

Inventions relying on the polypeptide having the amino acid sequence set forth in SEQ ID NO:11 or on the nucleic acid sequence comprising the sequence set forth in SEQ ID NO:12; methods of screening for biologically active agents that modulate a cancer associated phosphatase function; methods for diagnosis of cancer; methods for inhibiting the growth of a cancer cell; methods of screening for targets of a cancer associated phosphatase; methods to treat a tumour; compounds for the treatment of a tumour; methods for visualizing a tumour in a patient

INTERNATIONAL SEARCH REPORT

n on patent family members

ſ	Int Application No
	PCT/03/00393

	Patent document cited in search report			Patent family member(s)	Publication date
WO 0112	819 A	22-02-2001	AU CA EP JP WO	6903800 A 2377662 A1 1212433 A2 2003507016 T 0112819 A2	2 12-06-2002 25-02-2003
WO 0102	581 A	11-01-2001	AU AU CA EP JP WO WO	4206700 A 4367600 A 5783800 A 2377670 A1 1196598 A1 2003525027 T 0060092 A2 0102581 A1 0102582 A1	1 17-04-2002 26-08-2003 2 12-10-2000 1 11-01-2001
WO 0102	582 A	11-01-2001	AU AU CA EP JP WO WO	4206700 A 4367600 A 5783800 A 2377670 A1 1196598 A1 2003525027 T 0060092 A2 0102581 A1	1 17-04-2002 26-08-2003 2 12-10-2000 1 11-01-2001